Case Report

Pericardial Graft vs. Host Disease in a Patient with β-Thalassemia Major

Mehrdad Saravi MD1, Mohsen Vakili Sadeghi MD2, Hassan Mahmoodi Nesheli MD*

Abstract

Bone marrow transplantation (BMT) in young children improves results in β-thalassemia major. Graft versus host disease (GVHD) is an important complication of peripheral blood stem cell transplantation. GVHD affects heart with a behavior resembling an autoimmune disease, including pericardial effusion.

We describe a 22-year-old β-thalassemia major patient who underwent bone marrow transplantation with an HLA-identical sibling donor. The patient didn’t have any serious problem until 15 months after transplantation. He presented with chest discomfort and progressive dyspnea. Early echocardiogram showed mild pericardial effusion. Four days later, the effusion had increased, impending to cardiac tamponade. Immunospressive drugs and pericardectomy resulted in improvement of symptoms.

Cardiac cGVHD, an uncommon complication of HSCT may be presented as pericardial effusion. Although early initiation of steroids is very important, heart monitoring is necessary to diagnose cardiac tamponade.

Keywords: β-thalassemia major, BMT, GVHD, HSCT, pericarditis


Introduction

Hematopoietic stem cell transplantation (HSCT) is a new window to therapy of many diseases. In Iran, HSCT has been successfully adapted in a routine clinical care. HSCT in young children, before development of end-organ damage, improves results after transplantation for β-thalassemia major. Many post-transplant complications including, acute graft versus host disease (GVHD), chronic GVHD (c GVHD), hemorrhagic cystitis, VOD of liver, acute renal failure, and infections may occur. Many cardiac complications such as cardiomyopathies, pericarditis, heart failure, and arrhythmias may occur in (HSCT). Drugs used in conditioning regimen in HSCT are responsible factors for the cardiac toxicity. GVHD may affect heart and many other organs in the body, with a behavior resembling an autoimmune disease, including serositis (pleural/ pericardial effusion) and ascites. Also, cGVHD-associated serositis with or without pericarditis may occur mainly in the setting of treated as opposed to de novo chronic GVHD frequently in the setting of immunosuppression taper. GVHD is found as an important cause of death among other causes such as relapse, infections, and hemorrhagic cystitis, after bone marrow transplantation in many research centers. Several cardiac pathologic findings were seen in patients treated with bone marrow transplantation. Standard treatment of pericardial effusion (surgery and anti-inflammatory) offers poor results when recurrences occur.

Case Report

BMT was performed for a 22-year-old patient with β-thalassemia major who had an HLA-identical sibling, in July 2011. Conditioning regimen was busulfan, fludarabine and antithymocyt globulin. The patient was discharged from hospital on day 25 post transplantation. There were no intestinal, liver or cutaneous acute GVHD (aGVHD) at that time. Cyclosporine was administered as GVHD prophylaxis. Phlebotomy was done three times during the first 100 days of post transplantation, due to polycytemia. We decided to discontinue cyclosporine in the end of the first year of post transplantation. At that time oral cavity ulcer appeared. We considered this oral ulcer as a sign of graft vs. host disease. Gradually, sclerotic and erythematous skin lesions were progressed over the face and extremities. We treated these lesions as chronic GVHD with steroid and cyclosporine. He developed chest pain and progressive dyspnea 15 months after allogeneic peripheral blood stem cell transplantation. Vital signs revealed sinus tachycardia (110 beat per minute), and normal blood pressure (120/60 mm Hg). Heart sounds were normal. Surface electrocardiogram showed ST elevation in all leads, except V1 and aVR (Figure 1). Chest x-ray showed right-sided pleural effusion with clear lung fields and mild cardiomegaly. Trans-thoracic echocardiography showed the left ventricular ejection fraction of 55%, a thickened pericardium with mild pericardial effusion posterior of the left ventricle and anterior of the right ventricle without chamber collapse. Patient treated with CYA, mycophenolate mofetil (MM), and high dose corticosteroid. Four days later, the effusion had increased significantly (Figure 2) accompanying with chamber collapse and hypotension. We concluded that pericardial effusion occurred due to pericarditis and was considered as a manifestation of chronic GVHD in this
patient. The patient underwent a pericardiocentesis, evacuating approximately 250 ml of bloody pericardial fluid, which contained numerous lymphocytes, inflation, but no granulomatous cells. It was nonspecific suggesting of the inflammatory process and cGVHD. All microbiological studies (PCR for detection of CMV, herpes simplex I and II, human herpes 6, Epstein-Barr and varicella-zoster; bacterial, mycobacterial and fungal microscopy and culture) were negative. After two days, trans-thoracic echocardiography showed significant increase of the pericardial effusion. The patient was impending to cardiac tamponade requiring pericardectomy. Pericardectomy resulted in significant improvement in ventricular filling. The pericardial drainage tube was withdrawn after 5 days, and the patient was discharged from hospital on day 15. Treatment with prednisolone, MM and cyclosporine was continued. Skin GVHD didn’t improve with resolution of pericardial effusion. The patient had no cardiac problems after that.

**Discussion**

cGVHD is a common complication of HSCT, but rarely affects the heart. Cardiac cGVHD was characterized by insidious onset and mimics other pathologic factors. Manifestations of cardiac GVHD include pericardial effusion, coronary artery disease, and conduction disturbances. Although early initiation of steroids is very important, heart monitoring is necessary to diagnose cardiac tamponade. If the patient is impending to cardiac tamponade, pericardectomy should be done immediately. Our patient showed cardiac GVHD 15 months after BMT. Some study showed cardiac GVHD may be happened more than 15 months after allogenic
peripheral blood stem cell transplantation. Angelucci reported a case of acute cardiac tamponade without concurrent myocardial disease that occurred early after bone marrow transplantation in a thalassemia patient. Sclerotic and erythematous skin lesions on the face and extremities can help the diagnosis of cardiac cGVHD. It is important to rule out infections as a cause of pericarditis as same as Aoyama’s report. In their study, Aoyama, et al. reported pericarditis associated with EBV reactivation after allogeneic-stem cell transplantation. Pericardial constriction and restrictive cardiomyopathy should be considered as causes of breathlessness and/or edema that occur late after BMT. Silberstein described a man with Hodgkin’s disease who was transplanted from an HLA-identical brother, who developed cGVHD and constrictive pericarditis, 1 month after BMT. Jenner reported a successful response to infliximab of recurrent pericardial graft versus host disease, which we didn’t use.

In conclusions, cardiac cGVHD is an uncommon complication of HSCT. It may manifest as insidious onset and mimic other pathologic factors. Cardiac GVHD may present as pericardial effusion, coronary artery disease and conduction disturbances. Although early initiation of steroids is very important, heart monitoring is necessary to diagnose cardiac tamponade. If the patient is impending to cardiac tamponade, pericardectomy should be done immediately.

References

7. Jessica and Leonard, Chronic Gvhd-Associated Serositis and Pericarditis, Internal Medicine, Oregon Health & Science University.